Aegis Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 1.00 M
as on 16-11-2024
- Company Age 5 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.37 Cr
as on 16-11-2024
- Revenue 67.70%
(FY 2023)
- Profit 95.48%
(FY 2023)
- Ebitda 55.94%
(FY 2023)
- Net Worth 94.31%
(FY 2023)
- Total Assets 47.69%
(FY 2023)
About Aegis Lifesciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹5.37 Cr.
Rajeev Gupta, Neelam Gupta, and Ranil Gupta serve as directors at the Company.
- CIN/LLPIN
U24302GJ2019PTC106437
- Company No.
106437
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Feb 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Aegis Lifesciences Private Limited offer?
Aegis Lifesciences Private Limited offers a wide range of products and services, including Bandages & Dressing Disposables, Medical Gauze, Dentist Tools, Equipment & Supplies, Dental Implant Kit, Face Mask & Medical PPE Kits, Disposable Gloves, Oral Care Kit, Hospital Dressings, Eye Diagnosis & Surgery Instruments, Ophthalmic Surgical Instruments.
Who are the key members and board of directors at Aegis Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neelam Gupta  | Director | 05-Feb-2019 | Current |
| Rajeev Gupta | Director | 05-Feb-2019 | Current |
| Ranil Gupta | Director | 05-Feb-2019 | Current |
Financial Performance of Aegis Lifesciences.
Aegis Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 67.7% increase. The company also saw a substantial improvement in profitability, with a 95.48% increase in profit. The company's net worth Soared by an impressive increase of 94.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aegis Lifesciences?
In 2023, Aegis Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 04 Dec 2019 | ₹5.37 Cr | Open |
How Many Employees Work at Aegis Lifesciences?
Unlock and access historical data on people associated with Aegis Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aegis Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aegis Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED.webp){kind=small}
